News | November 03, 2021
Lancet endorses Sputnik Light for safety and immune response
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
New bioinformatic workflow advances analysis capabilities for whole-exome assessment and interpretation
Filing marks first protein-based vaccine submitted to MHRA for authorization
The Amplitude Solution gives laboratories the ability to scale Covid-19 PCR testing and process up to 8,000 samples a day
_256_384.jpg)
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
More than 90,000 patients utilise the services daily
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
Subscribe To Our Newsletter & Stay Updated
